

Beaucuo
pylori, and (iii) exhibits substantially no contribution to toxicity.

64. A method of treatment of an individual infected with *Helicobacter pylori* comprising administering an effective amount of the vaccine as defined in claim 48.

65. A method of treatment of an individual infected with *Helicobacter pylori* comprising administering an effective amount of the vaccine as defined in claim 51.

REMARKS

SECRET
In applicants' prior filed U.S. application Serial No. 08/471,491, filed June 6, 1995, in an Office Action dated November 26, 1996, the Examiner made a five-part restriction requirement in which Group I included original claims 4-5, 9-15, 17-19, 23-24 and 39, covering claims to the proteins including fragments thereof, vaccines and methods of preparation of vaccines and the proteins.


The claims of this application are solely drawn to the invention of Group I of applicants' 1995 application, which invention was part of the original claims in applicants' PCT/EP93/00472 application and for which applicants' declaration was made in 1994.

For the Examiner's information, applicants made a claim for priority benefit of their Italian application in the declaration of their March 2, 1993 PCT application; a certified copy of said Italian application with a sworn English translation thereof can be found in the file of applicants' PCT application.

An Information Disclosure Statement will be filed in due course. It is likely that the art cited by the Examiner and that included in the Information Disclosure Statement in applicants' parent application Serial No. 08/471,491 are the most pertinent to this invention as well.

Please call applicants' undersigned attorney if he can be of assistance in advancing the prosecution.

Respectfully submitted,


Francis A. Paintin
Registration No. 19,386

Date: *July 26, 1999*

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100